STOCK TITAN

10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

10x Genomics (Nasdaq: TXG) announced two research collaborations to identify blood-based biomarkers of autoimmune disease activity and treatment response.

The collaborations expand its autoimmune research to Europe and Asia. Charité – Universitätsmedizin Berlin and the German Rheumatology Research Center Berlin plan a multi-year, 750-patient study covering rheumatoid arthritis, systemic lupus erythematosus and psoriatic arthritis. It aims to identify and validate biological indicators distinguishing active from controlled disease and responders from non-responders to standard therapies.

Seoul National University researchers plan to study moderate-to-severe alopecia areata treated with JAK inhibitors, seeking indicators that may predict or reveal treatment response. Both collaborations plan to use Flex Apex to analyze blood samples collected over time at individual-cell resolution and link them with clinical data.

Loading...
Loading translation...

Positive

  • Minor point. Forward-looking: it has not happened yet and may not happen.European research collaboration plans a multi-year, 750-patient study to identify and validate disease-activity and treatment-response biomarkers.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Seoul National University collaboration aims to identify predictors and early indicators of JAK inhibitor response in alopecia areata.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Both collaborations will explore translating findings into future reporting frameworks for disease monitoring and treatment planning.

Negative

  • None.

Key Figures

Planned study enrollment: 750 patients
Planned study enrollment
750 patients
Multi-year Charité–DRFZ study

Key Terms

systemic lupus erythematosus, psoriatic arthritis, alopecia areata, jak inhibitor
4 terms
systemic lupus erythematosus medical
"systemic lupus erythematosus (SLE)"
Systemic lupus erythematosus is a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissue, causing inflammation that can affect skin, joints, kidneys, heart, lungs and other organs. It matters to investors because disease severity, prevalence, and gaps in effective treatments drive demand for new drugs and diagnostics—think of it as a large, persistent market need where a successful therapy can change patient outcomes and create significant commercial value.
psoriatic arthritis medical
"psoriatic arthritis (PsA)"
Psoriatic arthritis is a long-term inflammatory disease where the immune system causes both joint pain, swelling and stiffness and patches of scaly skin; think of it as the body’s defenses misfiring and damaging both skin and joints. It matters to investors because it defines a sizable, chronic patient population and drives demand for treatments, influencing drug development, regulatory approvals, pricing and healthcare spending.
alopecia areata medical
"focus on alopecia areata"
Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, causing round patches of hair loss on the scalp or body; severity ranges from small spots to widespread baldness. Investors watch it because successful treatments, clinical trial results, regulatory approvals, or shifts in prevalence can create or shrink markets for drugs and therapies, affecting the value of companies developing remedies—think of it as demand risk and regulatory risk for hair-loss products.
jak inhibitor medical
"patients with moderate-to-severe alopecia areata who received treatment with a JAK inhibitor therapy"
A JAK inhibitor is a type of medicine that blocks Janus kinase enzymes, which help cells send signals that drive inflammation and immune activity. By turning down that cellular “volume knob,” these drugs can reduce symptoms in autoimmune diseases and certain blood disorders. Investors watch JAK inhibitors because their effectiveness, safety profile, approval status, and patent position directly affect drug sales, market competition, and regulatory risk for companies developing or selling them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform

PLEASANTON, Calif., Nov. 16, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease. The first collaboration is with Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals, and the German Rheumatology Research Center Berlin (DRFZ). The second is with the Genomic Medicine Institute at Seoul National University (SNU), one of South Korea's leading research universities.

10x Genomics Logo

Earlier this year, 10x outlined its clinical strategy for realizing the potential of single cell and spatial technologies in diagnostics, with a focus on oncology and autoimmune disease. These two new collaborations expand 10x's autoimmune disease research to Europe and Asia. Both collaborations plan to use Flex Apex to analyze longitudinal blood samples at single cell resolution. By pairing these profiles with clinical data, researchers aim to identify biomarkers of disease activity and treatment response.

"Clinical decision-making in autoimmune disease depends on symptoms and tests that provide only indirect measures of underlying immune activity, while treatment selection relies on trial and error," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "By studying longitudinal cohorts across diseases, therapies and geographies, these collaborations can help identify robust, reproducible biomarkers of disease activity and treatment response. That evidence could lay the foundation for a new generation of blood-based diagnostics built on single cell measurements of immune activity, moving us closer to precision medicine for patients with autoimmune disease."

Charité and DRFZ: Disease Activity and Treatment Response in Rheumatoid Arthritis, Lupus and Psoriatic Arthritis

10x, Charité and DRFZ plan to conduct a multi-year study involving 750 patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA). Patients will be followed longitudinally as they begin or adjust biologic or targeted therapies, with blood collected during routine clinical visits.

Using Flex Apex, researchers intend to profile immune cells in the blood and connect changes in cellular states and biological pathways with clinical measures of disease activity. The study aims to identify and validate biomarkers that distinguish active from controlled disease and responders from non-responders to standard-of-care therapies

"Patients with the same rheumatic disease can follow very different courses and respond differently to the same therapy," said Gerhard Krönke, Director of the Department of Rheumatology and Clinical Immunology at Charité. "Following patients over time will allow us to connect shifts in immune biology with clinical outcomes, which is essential to improving care."

"Single cell profiling across a cohort of this size allows us to examine immune activity at a depth not captured by conventional inflammatory markers," said Eicke Latz, Scientific Director of the German Rheumatology Research Center (DRFZ). "Our goal is to identify robust biomarkers that are consistent across diseases, therapies and patient populations."

Seoul National University: Predicting Response to JAK Inhibitors in Alopecia Areata

The study with SNU will focus on alopecia areata, an autoimmune disease that can cause hair loss. The collaboration brings together the Genomic Medicine Institute (GMI) and researchers from SCAID, building on patient cohorts and biospecimens established through the SCAID research program. Researchers plan to use Flex Apex to analyze longitudinal blood samples from patients with moderate-to-severe alopecia areata who received treatment with a JAK inhibitor therapy.

By comparing immune profiles before and during treatment with clinical outcomes, the collaboration aims to identify baseline biomarkers that may predict treatment response and early molecular changes that may indicate whether a patient is responding. Researchers will also examine biological differences among patients who respond quickly, respond more slowly or do not respond to treatment.

"Patients with alopecia areata can respond differently to JAK inhibitor therapy. By linking longitudinal single-cell immune profiles with clinical outcomes, we aim to understand the biology underlying these differences and identify candidate biomarkers of treatment response. We hope this work will provide a foundation for more informed treatment decisions in the future," said Professor Jong-Il Kim, Head of the Genomic Medicine Institute (GMI) of Seoul National University.

Both collaborations will explore how findings could be translated into future reporting frameworks for disease monitoring and treatment planning.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

About Charité – Universitätsmedizin Berlin
With more than 100 departments and institutes spanning four campuses, Charité – Universitätsmedizin Berlin is one of Europe's largest university medical centers. As a cutting-edge medical institution, Charité is a leader in the diagnosis and treatment of severe, complex and rare diseases. Combining first-class patient care with excellence in research and innovation, state-of-the-art teaching, and high-quality training and education, Charité has earned an outstanding reputation worldwide as both a medical school and a university medical centre.

About the German Rheumatology Research Center Berlin
The DRFZ is a Leibniz Institute dedicated to improving the understanding, diagnosis, treatment, and care of people with immune‑mediated rheumatic diseases. The institute combines basic research, systems biology, translational research, and epidemiology with state‑of‑the‑art technologies to develop preventive approaches and personalised—potentially curative—treatments. Using nationwide data and large patient cohorts, the DRFZ assesses disease burden, identifies risk factors, uncovers gaps in health care, and evaluates how well therapies work in real life. These insights guide the research and help ensure that new discoveries lead to meaningful improvements in patients' lives.

About the Genomic Medicine Institute at Seoul National University
The Genomic Medicine Institute (GMI) is part of the Medical Research Center at Seoul National University. This collaboration involves researchers from SCAID, a research program initiated in 2022 to build single-cell maps of immune-mediated diseases using patient blood and tissue samples.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-expands-global-research-in-blood-based-diagnostics-for-autoimmune-disease-with-two-new-collaborations-302940831.html

SOURCE 10x Genomics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who are 10x Genomics' new autoimmune disease research partners?

10x Genomics is collaborating with Charité – Universitätsmedizin Berlin and the German Rheumatology Research Center Berlin, and separately with Seoul National University's Genomic Medicine Institute. The collaborations focus on identifying blood-based indicators of autoimmune disease activity and treatment response.

How will patients be followed in 10x Genomics' Charité and DRFZ study?

Patients will be followed over time as they begin or adjust biologic or targeted therapies, with blood collected during routine clinical visits. Researchers intend to connect changes in immune-cell states and biological pathways with clinical measures of disease activity.

Keep reading